Therapeutic considerations in applying rate control therapy for atrial fibrillation

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 1, 2008, Pages 11-17

  Wyse, D George ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Activity heart rate; Atrial fibrillation; Heart rate control; Heart rate regularity; Modes of therapy; Resting heart rate

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; ANTIARRHYTHMIC AGENT;

ADD ON THERAPY; ATRIOVENTRICULAR CONDUCTION; DEATH; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; EXERCISE; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART OUTPUT; HEART RATE; HEART RHYTHM; HEART VENTRICLE PACING; HUMAN; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SINUS RHYTHM; STROKE; HEART MUSCLE CONDUCTION SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS;

EID: 55949119361     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31816d5f49     Document Type: Review

References (24)

1. Rawles JM: What is meant by a controlled ventricular rate in atrial fibrillation? Br Heart J. 1990;63:157-161.
2. Kerr AJ, Williams MJA, Stewart RAH. Ventricular rate and beta-to-beat variation of stroke volume in atrial fibrillation. Am J Cardiol. 2001;87: 1116-1119.
3. Daoud EG, Weiss R, Bahu M, et al. Effect of irregular ventricular rhythm on cardiac output. Am J Cardiol. 1996;78:1433-1436.
4. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 Guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines. Circulation. 2002;106:2145-2161.
5. Van Gelder IC, Wyse DG, Chandler ML, et al. Does the intensity of ratecontrol influence outcome in atrial fibrillation. An analysis of pooled data from the RACE and AFFIRM studies. Europace. 2006;8:935-942.
6. Matsumoto M, Yamashita T, Fukdua E, et al. Variability of ventricular response intervals and exercise capacity in patients with non-valvular atrial fibrillation. Circ J. 2004;68:294-296.
7. Hossack KF, Bruce RA. Maximal cardiac function in sedentary normal men and women: comparison of age-related changes. J Appl Physiol. 1982;53:799-804.
8. Lukl J, Doupal V, Sovova E, et al. Incidence and significant of chronotropic incompetence in patients with indications for primary pacemaker implantation or pacemaker replacement. Pacing Clin Electrophysiol. 1999;22:1284-1291.
9. Rokas S, Gaitanidou S, Chatzidou S, et al. A noninvasive method for the detection of dual atrioventricular node physiology in chronic atrial fibrillation. Am J Cardiol. 1999;84:1442-1445.
10. Lauer M, Froelicher ES, Williams M, et al. Exercise testing in asymptomatic adults: a statement for professionals from the American Heart Association Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation. 2005;112:771-776.
11. Lombardi F, Tarricone T, Tundo F, et al. Autonomic nervous system and paroxysmal atrial fibrillation: a study based on the analysis of RR interval changes before, during and after paroxysmal atrial fibrillation. Eur Heart J. 2004;25:1242-1248.
12. Olshansky B, Rosenfeld LE, Warner AL, et al. Green HL and the AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43:1201-1208.
13. McNamara RL, Tamariz LJ, Segal JB, et al. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med. 2003;139:1018-1033.
14. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for Management of Patients with Atrial Fibrillation). J Am Coll Cardiol. 2006;48:e149-e246.
15. Nikolaidou T, Channer KS. Rate control in atrial fibrillation. Br Med J. 2007;335:1057-1058.
16. Wittkampf FH, de Jongtse MJ, Lie HI, et al. Effect of right ventricular pacing on ventricular rhythm during atrial fibrillation. J Am Coll Cardiol. 1988;11:539-545.
17. Simpson CS, Yee R, Lee JK, et al. Safety and feasibility of a novel ratesmoothed ventricular pacing algorithm for atrial fibrillation. Am Heart J. 2001;142:294-300.
18. Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimulation Post AV nodal ablation Evaluation (The PAVE Study). J Cardiovasc Electrophysiol. 2005;16:1160-1165.
19. Giudici MC, Thornburg GA, Buck DL, et al. Comparison of right ventricular outflow tract and apical lead permanent pacing on cardiac output. Am J Cardiol. 1997;79:209-212.
20. Feld GK, Fleck RP, Fujimura O, et al. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation. 1994;90:2299-2307.
21. Bradley DJ, Shen WK. Atrioventricular junction ablation combined with either right ventricular pacing or cardiac resynchronization therapy for atrial fibrillation: the need for large-scale randomized trials. Heart Rhythm. 2007;4:224-232.
22. Lee SH, Chen SA, Tai CT, et al. Comparisons of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular junction modification in patients with medically refractory atrial fibrillation. J Am Coll Cardiol. 1998;31:637-644.
23. Wyse DG. Rate control vs. rhythm control strategies in atrial fibrillation. Prog Cardiovasc Dis. 2005;48:125-138.
24. Van Gelder IC, Van Veldhuisen DJ, Crijns HJ, et al. Rate control efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J. 2006;152:420-426.